Patterns and Clinical Impact of Alectinib Dose Reduction in Patients with ALK-Positive Non- Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
To, B. [1 ]
Farid, S. [1 ]
Zhao, S. [1 ]
Li, M. [1 ]
Amirmokhtari, N. [1 ]
Wei, L. [1 ]
Memmott, R. [1 ]
Alahmadi, A. [1 ]
He, K. [1 ]
Kaufman, J. [1 ]
Roof, L. [1 ]
Shields, P. [1 ]
Carbone, D. [1 ]
Otterson, G. [1 ]
Presley, C. [1 ]
Owen, D. [1 ]
机构：
[1] Ohio State Univ, Med Ctr, Columbus, OH USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
alectinib; dose reduction; CNS disease;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12B.10
引用
收藏
页码：S644 / S645
页数：2
相关论文
共 50 条
  • [1] Clinical effect of alectinib in patients with ALK-positive non-small cell lung cancer
    Nishi, Koichi
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Alectinib for ALK-positive non-small-cell lung cancer
    Rossi, Antonio
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (08) : 1005 - 1013
  • [3] Alectinib in resected ALK-positive non-small-cell lung cancer
    Gourmet, Anais
    Ferrari, Victoria
    BULLETIN DU CANCER, 2024, 111 (10) : 905 - 906
  • [4] Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Dziadziuszko, Rafal
    Ahn, Jin Seok
    Barlesi, Fabrice
    Nishio, Makoto
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Mao, Weimin
    Hochmair, Maximilian
    de Marinis, Filippo
    Migliorino, M. Rita
    Bondarenko, Igor
    Lu, Shun
    Wang, Qun
    Ochi Lohmann, Tania
    Xu, Tingting
    Cardona, Andres
    Ruf, Thorsten
    Noe, Johannes
    Solomon, Benjamin J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14): : 1265 - 1276
  • [5] Alectinib for treatment of ALK-positive non-small-cell lung cancer
    Avrillon, Virginie
    Perol, Maurice
    FUTURE ONCOLOGY, 2017, 13 (04) : 321 - 335
  • [6] Alectinib for advanced ALK-positive non-small-cell lung cancer
    Ly, Ashley C.
    Olin, Jacqueline L.
    Smith, Morgan B.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (08) : 515 - 522
  • [7] Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
    Karachaliou, Niki
    Fernandez Bruno, Manuel
    Paulina Bracht, Jillian Wilhelmina
    Rosell, Rafael
    ONCOTARGETS AND THERAPY, 2019, 12 : 4567 - 4575
  • [8] Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer
    Burudpakdee, C.
    Wong, W.
    Seetasith, A.
    Corvino, F. A.
    Yeh, W.
    Gubens, M.
    LUNG CANCER, 2018, 119 : 103 - 111
  • [9] Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer
    Yoshida, Hironori
    Kim, Young Hak
    Ozasa, Hiroaki
    Sakamori, Yuichi
    Tsuji, Takahiro
    Nomizo, Takashi
    Yasuda, Yuto
    Yamamoto, Tomoko
    Ajimizu, Hitomi
    Hirai, Toyohiro
    IN VIVO, 2018, 32 (06): : 1587 - 1590
  • [10] Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
    Yu, Hui
    Sun, Si
    Hu, Xingjiang
    Xia, Jinjing
    Wang, Jialei
    Chen, Haiquan
    ONCOTARGETS AND THERAPY, 2019, 12 : 6481 - 6495
12345